A LC-MSMS method for the simultaneous determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots samples was developed and validated. The method employs an ultrasound-assisted liquid extraction and a reversed phase separation in an Acquity s C18 column (150 Â 2.1 mm, 1.7 mm). Mobile phase was a mixture of formic acid 0.1% (v/v) pH 2.7 and acetonitrile (gradient from 60:40 to 50:50, v/v). Total analytical run time was 8 min. Precision assays showed CV % lower than 10.75% and accuracy in the range 94.5 to 110.3%. Mean analytes recoveries from DBS ranged from 40% to 92%. The method was successfully applied to 91 paired clinical DBS and plasma samples. Dried blood spots concentrations were highly correlated to plasma, with rs40.83 (Po 0.01). Median estimated plasma concentrations after hematocrit and partition factor adjustment were: TAM 123.3 ng mL À 1 ; NDT 267.9 ng mL À 1 , EDF 10.0 ng mL À 1 and HTF 1.3 ng mL
Introduction
Tamoxifen (TAM) [trans-1-(4-β-dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene] has been the mainstay hormonal treatment for breast cancer for more than 30 years, with significant impact on the survival rates of patients. However, besides the therapeutic benefits of TAM in the general population, 30 to 50% of patients under TAM pharmacotherapy have tumor recidives or present resistance to the treatment [1] .
The usual presentation of TAM is TAM citrate tablets, containing 10 or 20 mg of the pure trans isomer, with the recommended posology of 20 mg per day. TAM pharmacologic activity is dependent of its bioativation by cytochrome P 450 enzymes [2, 3] . CYP3A4 and 3A5 convert TAM to N-desmethyltamoxifen (NDT), this being the largest primary metabolic route. NDT undergoes 4-hydroxylation via CYP2D6, being biotransformed into 4-hydroxy-N-desmethyltamoxifen or (Z)-endoxifen (EDF). CYP2D6 also catalyzes the metabolism of TAM to 4-hydroxy-TAM (HTF) [4] . The antiestrogenic activity of TAM is mainly due to EDF, which, as HTF, is up to 100 times more potent to inhibit the proliferation of Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/talanta estrogen-dependent cells, and usually have plasma concentrations up to 6 times higher than HTF [5] .
EDF plasma concentrations were widely variable among patients, what could be explained by polymorphisms in the gene encoding CYP2D6 and by interactions with enzyme modulating agents, leading to insufficient plasma EDF levels in many individuals [6] . Along CYP2D6, CYP3A and CYP2C9 enzymes were related to EDF formation, but to a lesser extend [2] . Recently, Teft et al. [7] described reduced EDF plasma concentrations during the winter months, which was associated to low plasma 25-hydroxyvitamin D levels. These authors suggested that CYP3A4 activity together with sunlight exposure is an underscored factor in the evaluation of the therapeutic efficacy of TAM.
In a recent clinical study, Madlensky et al. [8] exploited the relation between the clinical outcome of hormonal therapy and serum concentrations of TAM and its metabolites, suggesting that adequate therapeutic outcome is dependent to the achievement of a threshold EDF concentration. Patients presenting trough EDF plasma levels above 5.9 ng mL À 1 had a 26% reduction of recurrences comparing with patients with EDF concentrations below this threshold. These findings, along with the increasing knowledge about TAM metabolism modulating agents, encouraged studies with individualized dose adjustments, with increased doses for patients with impaired EDF formation (30 or 40 mg day
) [9] [10] [11] . Moreover, the metabolic ratio [NDF]/[EDF] has been described as an appropriate surrogate of CYP2D6 activity, rendering useful clinical information about TAM metabolism [5] . Considering the available evidence, therapeutic drug monitoring of TAM and its main metabolites during hormonal therapy of breast cancer could be an important tool to obtain optimal pharmacological response, recognizing patients eligible to higher TAM doses or alternative pharmacotherapy.
Several methods for the measurement of TAM and metabolites in serum or plasma samples were described [6, [12] [13] [14] . To obtain these conventional samples, it is necessary to perform a phlebotomy in a proper facility, also considering pharmacokinetically appropriated collection times. A novel option for therapeutic drug monitoring that has been emerging recently is testing in dried blood spots on paper (DBS), collected by finger prick [15] [16] [17] , mainly due to the stabilization of the analytes by drying and the possibility of postal transportation, once DBS samples are usually non-bio hazardous. Also, this novel matrix allows the possibility of training patients to take their own samples and flexible collection times, more adequate to their personal posology [18] .
The use of DBS for TAM and metabolites measurements could be a very useful strategy to optimize the use of this drug in breast cancer, potentially allowing continuous monitoring of EDF levels during a long-time treatment, without requiring patients to come to a specialized center. However, considering the small blood volume present in a DBS obtained after a finger prick and the low concentrations of TAM and metabolites, especially EDF, this application requires highly sensitive analytical methods. In view of the above, the objective of this study was to develop and validate a method for determination of TAM and its metabolites NDT, EDF e HTF in DBS using ultra performance liquid chromatographypositive electrospray ionization tandem mass spectrometry and evaluate its performance in clinical samples of breast cancer patients.
Experimental

Reagents, materials and reference standard samples
Tamoxifen, 4-hydroxy tamoxifen e clomifen citrate (E/Z) were acquired from Sigma (Saint Louis, USA). N-desmethyl tamoxifen chloridrate and N-desmethyl-4-hidroxy tamoxifen (E/Z) were obtained from Toronto Research Chemicals (North York, Canada). Tris(hidroxymethyl)aminomethane was obtained from Nuclear (Diadema, Brazil). Formic acid, metanol, acetonitrile, n-propanol and hexane (60% n-hexane) were bought from Merck (Darmstadt, Germany 
Sample preparation
Quality control and calibration samples were prepared by pipetting 60 mL aliquots of spiked blood onto Whatman 903 paper and leaving them to dry at room temperature for 3 h before processing. DBS discs were obtained by perforation, using a 10 mm punch cutter, and two discs were used for extraction. Discs were cut in half, transferred to polypropylene microtubes and 1000 μL of extraction solution was added (clomifene 0.1 ng mL À 1 in methanol), followed by 1 min vortexing. After 45 min h in an ultrasonic bath, 850 μL of extract was transferred to a clean polypropylene microtube and dried at 55 1C under a gentle stream of air. The dried extract was recovered with 100 mL of mobile phase, transferred to an autosampler vial and a 25 μL aliquot was injected into the LC-MS/MS system.
UHPLC-MS-MS equipment and conditions
Samples were analyzed using a TSQ Quantum Access triple quadrupole mass spectrometer with an electrospray source, coupled to an Ultimate 3000 XRS UHPLC system, controlled by the Xcalibur software, all from Thermo Scientific (San Jose, USA). Separation was performed in an Acquity C18 column (150 Â 2.6 mm, p.d. 1.7 μm) from Waters (Milford, USA), maintained at 50 1C and eluted at a mobile phase flow rate of 0.4 mL min . The mobile phase consisted of formic acid 0.1% pH 2.7 (eluent A) and acetonitrile plus 0.1% formic acid (eluent B). Initial eluent composition was 60% A, maintained for 3 min, and followed by a linear 1 min ramp to 50%, which was maintained for until 5.5 min. The mobile composition returned to 60% A at 6 min. Equilibration time was 2 min.
Injection volume was 25 μL. The MS conditions were as follows: electrospray ionization (ESI), positive mode, capillary voltage of 4 kV; sheath gas, nitrogen at a flow rate of 50 arbitrary units; auxiliary gas, nitrogen at flow rate of ten arbitrary units; collision gas, argon; vaporizer temperature, 400 1C; and ion transfer capillary temperature, 220 1C. 
Selectivity
Blank DBS samples obtained from 6 different human sources were prepared as described above to check for the presence of chromatographic peaks that might interfere with detection of analytes or IS.
Benchtop stability
For estimation of stability of processed samples under the conditions of analysis, control DBS samples were extracted as described above, in sextuplicate. Quality control low (QCL) samples had TAM, NDT, EDF e HTF at 21.0; 45.0; 3.0 and 1.8 ng mL The extracts obtained at each concentration were pooled. Aliquots of these pooled extracts at each concentration were transferred to autosampler vials and injected under the conditions of a regular analytical run at time intervals of 1 h, during 12 h. Stability of analytes was tested by regression analysis plotting absolute peak areas corresponding to each compound at each concentration vs. injection time. Using the obtained linear regression, the concentration after 12 h was calculated. A decrease or increase of up to 10% in the measured peak areas was considered as acceptable.
Stability of analytes in DBS at varying temperatures
For evaluation of thermal stability of TAM and metabolites in DBS samples, quality control DBS samples (QCL and QCH), previously described, were maintained at À20 1C, 25 1C e 45 1C and analyzed (triplicate) on days 2, 6, 8, 10, 13, 15, 17 e 20 after spotting in the paper. Stability was considered acceptable if all results were within the range of 85-115% of the concentrations measured at the beginning of the series.
Linearity
Aliquots of 950 μL blank blood (Hct 35%), were enriched with 50 μL of the corresponding stock solutions to obtain seven calibration levels of samples containing TAM (300, 225, 150, 75, 30, 15, 7.5 ng mL paper (12 Â 60 mL for each level), dried at room temperature and analyzed within 24 h. Replicates (n ¼6) at each concentration were analyzed as described at item 2.5. Calibration curves were calculated relating the area ratios from TAM, NDT, EDF and HTF peaks to the IS peak and with the nominal concentrations of the calibration samples. Homoscedasticity of calibration data was evaluated with F-test at the confidence level of 95%. Curves were fitted using least-squares linear regression using several weighting factors (1/x, 1/x 2 , 1/y, 1/y 2 ). Calibration models were assessed using coefficients of correlation (r) and cumulative percentage relative error (∑%RE) [19] . Daily calibration curves using the same concentrations (single measurement at each concentration level) were analyzed with each batch of validation and clinical samples.
Precision and accuracy
Aliquots of blank blood were enriched with methanolic solutions and applied to paper to obtain quality control DBS samples containing TAM, NDT, EDF and HTF at concentrations of 21.0; 45.0; 3.0 and 1.8 ng mL , respectively (quality control high, QCH). Control samples were maintained at room temperature and analyzed within 24 h as item 2.5. The quality control samples were analyzed as described above in triplicate on each of 5 days. Withinassay precision and between-day precision were calculated by oneway ANOVA with the grouping variable "day" and were expressed as CV%. Accuracy was defined as the percentage of the nominal concentration represented by the concentration estimated with the calibration curve. The acceptance criteria for accuracy were mean values within 715% of the theoretical value and for precision a maximum CV of 15% was accepted [20] .
Lower limit of quantification
An independent DBS quality control sample at the lowest point of the calibration curve at concentrations of 7.5; 15.0; 1.0; 0.5 ng mL À 1 for TAM, NDT, EDF and HTF, respectively, was included in the accuracy and precision experiments (quality control at the limit of quantitation, QCLOQ) and was tested in triplicate in three different days. The acceptance criteria established for the limit of quantification was accuracy within 100 7 20% of the nominal value and an imprecision with of maximum 20% [20] .
Influence of hematocrit on analytes concentrations assayed in DBS samples
Aliquots of blood containing different Hct% (25, 30, 35 , 40, 45 and 50%) were prepared by centrifuging EDTA whole blood and then combined with appropriate volumes of cells and plasma. TAM and metabolites were added to these aliquots of blood to achieve concentrations of QCL: 21.0; 45.0; 3.0 and 1.8 ng mL À 1 and QCH:
210.0; 450.0; 30.0 and 18.0 ng mL À 1 for TAM, NDT, EDF and HTF, respectively, which were then pipetted onto Whatman 903 paper, followed by drying at room temperature for 3 h. The DBS obtained were analyzed in triplicate for each concentration and Hct% as described in item 2.5. The influence of the Hct% on TAM and metabolites measurements was determined as the percentages of nominal concentrations that were actually measured in the DBS.
Matrix effect and extraction yield
Matrix effect was evaluated by a post-extraction spike method. Three series of quality control samples (QCL, QCM and QCH) were prepared in order to assess extraction yield and matrix effect on ionization as follows: (A) solutions of TAM, metabolites and IS prepared in mobile phase solutions in order to obtain final concentrations equivalent to 100% extraction yield and directly injected onto column. (B) DBS extracts samples from 5 different sources (mixed before application on paper), post-extraction spiked with TAM, metabolites in mobile phase containing IS. (C) DBS extracts samples from 5 different sources (mixed before application on paper) enriched with TAM and metabolites before extraction. Each quality control sample was analyzed in quintuplicate. Matrix effect (ME) on ionization was estimated as the percentages of reduction or increase of TAM, NDT, EDF, HTF and IS areas on post-extraction spiked (B), comparing to directly injection of solutions (B), calculated as ME¼[100%À (B/A%)]. Extraction yields (EY) were calculated comparing the analyte/IS area ratio before extraction (C) and after extraction (B), using the formula EY¼ C/B%.
Application of the method
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Research Ethics Committee at the Hospital de Clínicas de Porto Alegre. A total of 91 patients on adjuvant hormonal treatment with tamoxifen (20 mg day À 1 ) for at least 4 months were enrolled in the study with informed consent. Data on age, weight, body mass index (BMI), race, compliance (obtained from the number of TAM tablets taken monthly) and menopause status were recorded, in addition to the duration of TAM therapy and any concomitant therapies considered as CYP2D6 inhibitors. Blood samples were taken 18-24 h after the last TAM intake, patients being fasten for 4 h. Capillary blood was collected after finger prick using a 2.0 mm penetration, 0.8 mm blade contact-activating lancet (Medlance s ). Blood spots were collected on 2 circles of the Whatman 903 DBS card and allowed to dry for at least 3 h at room temperature. Analyses were performed within 3 days. Venous blood was simultaneously collected within an interval of 715 min by venipuncture into two EDTA tubes. One tube was used for Hct% determination, the other was immediately centrifuged and plasma was transferred to polypropylene tubes, stored at À 70 1C until analysis within one month. Concentrations of TAM, NDT, EDF and HTF were measured through daily calibration curves and estimated plasma concentrations (EPC) were obtained after adjustment of DBS concentrations by patients Hct % and use of a correction factor, as follows:
Correction factors were estimated so that the ratio of mean DBS to mean plasma levels would be equal to 1. 
Determination of TAM and metabolites in plasma
Statistical analysis
Initially, a descriptive analysis of the study variables was conducted. The precision validation parameters were evaluated using ANOVA. Medians and 25% and 75% percentiles for TAM, NDT, EDF, HTF levels and metabolic ratio [NDT]/[EDF] were determined. Analytes in DBS (y) vs measured plasma concentrations (x), as well as estimated plasma (y) vs measured plasma concentrations (x) were assessed by Passing-Bablok regression [21] and Spearman correlation. The presence of outliers and tendencies were evaluated using Bland Altman plots [22] of estimated plasma concentrations vs measured plasma concentrations as well as DBS vs measured plasma concentrations. Acceptation criteria for the agreement between estimated and measured plasma concentrations were based on the guideline on Bioanalytical Method Validation of the EMA, the difference in concentration should be within 720% of their mean for at least 67% of the samples [23] .
The 
Results and discussion
Chromatography and preparation of samples
The LC-MS/MS system proved to be an appropriate system for determination of TAM and its main metabolites in DBS samples. TAM, NDT, HTF and EDF are structurally very similar, with demethylation and/or hydroxylation, resulting in slight differences of polarity. Reversed phase C18 columns appeared appropriate to separate TAM metabolites [24] . In this study an Acquity s C18 column (150 Â 2.1 mm, 1.7 mm) was used, separating TAM and the 3 metabolites in a 8 min run, with reduced mobile phase consumption of 3.2 mL per analysis. Retention times were 2.77 min for EDF, 3.02 min for HTF, 5.85 min for IS, 6.07 min for NDT and 6.31 min for TAM. Fig. 1 illustrates chromatograms from DBS and plasma samples. No interfering compounds were identified in the 6 DBS samples processed free from TAM and analytes. Additionally, the tandem mass spectrometry results in inherent specificity analysis, in which chromatograms are monitored through the transition of molecular ion to three products (1 quantifying and 2 confirmatory ions).
Sample preparation was simple, based on ultrasound-assisted liquid extraction of analytes from paper punches containing approximately 90 mL of blood. Extraction yield was higher for the least polar compounds, with average of 91.5% for TAM and 84.8% for NDT, comparing to 47.5% for (Z)-(Z)-EDF and 39.6% for HTF. Besides the lower extraction recoveries of EDF and HTF, the method presented satisfactory sensitivity considering the extent of concentrations found in clinical samples, with LLOQ of 1.0 ng mL À 1 for EDF and 0.5 ng mL À 1 for HTF [25, 14, 11, 26] .
Method validation
Extracts from DBS containing TAM and metabolites at QCL and QCH concentrations were stable during the 12 h bench stability test, with maximum variation in analytical response of 9.2%, indicating that large batches can be analyzed without taking special measures to preserve extracts. Calibration data exhibited significant heteroscedasticity, with F exp ranging from 495.1 to 1237.0 (F tab (6; 5; 0.95) ¼ 4.95). The regression using a weighting factor of 1/x offered the best ∑%RE of the models tested, with values below 1 Â 10 À 9 and this weighting factor was used for all subsequent validation tests and for analysis of the clinical samples. The coefficients of correlation were above 0.99 for all weighting factors. The results of the precision and accuracy experiments, assessed by analyzing low, medium and high concentration quality control samples, were satisfactory, as shown in Table 1 . Intra-assay imprecision were in the range of 5.13 to 12.30% and inter-assay imprecision was 5.10 to 11.54%, demonstrating that the method is adequately repeatable. Accuracy was estimated at 94.6 to 110.3%, which is also within the limits of acceptance for bioanalytical methods recommended by Shah et al. [20] . The quality control samples at the lower limit of quantification (LLOQ) of 7.5; 15; 1.0; 0.5 ng mL À 1 for TAM, NDT, EDF and HTF presented acceptable imprecision (from 7.01 to 12.07%) and accuracy (90.6 to 97.5%). Due to its high specificity and sensitivity LC-MS/MS is considered as the method of choice for quantitative analysis of compounds in biological matrices. However molecules originating from the sample matrix that coelute with the compounds of interest can interfere with the ionization process, causing ion suppression or enhancement [27] . Post-extraction spiked method analysis showed (Z)-EDF and HTF ionization suppression within 12% and IS ionization enhancement effect of 8%, indicating that coeluting matrix components appear to have a minimal effect on the considered analytes. TAM and NDT demonstrated to be more affected by matrix effect with average suppression of 22.9 and 34.7% respectively. Similar observation was pointed out on a previously described LC-MS/MS method [28] , where matrix ionization suppression (plasma samples) was larger for NDT (38% area reduction) comparing to other TAM metabolites.
As reported above, matrix components do influence to some extent TAM and NDT ionization and consequently the overall process efficiency, requiring therefore the preparation of calibration and control samples in a DBS matrix reflecting at best the composition of the samples to be analyzed. More important that the absolute matrix effect, no significant variability among concentrations and samples was observed in our method. Additionally, TAM and NDT presented high extraction yields ( 481%), allowing analysis with satisfactory sensitivity and linearity range comprising clinical samples concentrations after a 20 mg/daily intake of TAM [25, 11, 26] .
Thermal stability was also tested in DBS samples at the concentrations of QCL and QCH after storage at À 20 1C, 25 1C and 45 1C up to 20 days. These temperatures were selected to simulate conditions that samples sent by regular mail could potentially be exposed. No changes were observed neither for TAM nor for NDT on DBS stored over a period of 20 days at the tested temperatures (maximum variance of 14%). However, (Z)-EDF and HTF were stable at À20 and 25 1C (maximum variance of 15%) but not at 45 1C, with an increase on concentrations, which ranged from 38% at day 2, to 47% after 20 days. In absence of any data in the literature regarding TAM and metabolites stability on DBS samples, we assumed that increase of metabolite concentrations at higher temperature could be the consequence of TAM and NDT degradation. Tested EDF and HTF levels were approximately 10 fold lower than TAM and NDT, therefore more likely affected by any minor changes in TAM and NDT concentrations. Another possible explanation for this finding could be the production of isobaric interfering compounds on DBS samples under high temperatures. Both hypotheses should be further tested.
Information about the thermal, light, and chemical stability of the analytes in DBS matrix must be available in order to explore its logistic advantages. When using transport by regular mail it is important to be aware that the inner temperature of mailboxes in full sun exposure can reach about 60 1C in summer months [29] . Up to now there is no data in the literature regarding the stability of EDF and HTF in DBS samples. Considering our findings on EDF and HTF stability and the high temperatures during summer time, it is reasonable to recommend that temperature during transport and storage of DBS cards for TAM and metabolites measurement should be controlled and not exceed 25 1C. 
Impact of hematocrit on determination of TAM and metabolites
The impact of different Hct% levels on calculated concentrations of TAM and metabolites during analysis of DBS samples was tested at concentrations of QCL and QCH prepared in blank blood with Hct% ranging from 25 to 50 and quantified by analytical curves prepared using blood with Hct% of 35. Variation from nominal concentrations found in control samples were within 713% for Hct 25%, 710% for Hct 30%, 710% for Hct 35%, 78% for Hct 40%, 716% for Hct 45% and 720% for Hct 50%. Highest variations from target were found at Hct 45% and 50% and were above 15% which was the cutoff for acceptability. This is probably due to increased viscosity of the blood and hence reduced dispersion through the paper. In contrast, DBS prepared with blood with Hct percentages ranging from 25 to 40 presented results within the range of acceptability (87-108%). On this basis, analytical curves prepared using blood with Hct% of 35 are applicable to samples from patients with Hct% within 25-40, covering most of patients Hct% range (30.6 to 43.6, mean 36). Seven patients had Hct% above 40, where calculated concentrations have to be corrected accordingly.
Besides DBS samples being obtained from capillary blood, venous blood was used to determine the patient Hct%, considering the absence of difference between capillary and venous Hct% [29] . Yang et al. [30] also found no difference between Hct% measured in venous and capillary blood.
Clinical application and method comparison
A total of 91 patients on adjuvant hormonal treatment with tamoxifen (20 mg day patients were Caucasian and 16 were brown (parda-a Brazilian national census classification) or black. Hot flashes were the major adverse effect (51.6%). Eighteen patients (19.8%) reported concomitant use of CYP2D6 inhibitors drugs: 11 on weak inhibitors (e.g. venlafaxine, citalopram and haloperidol) and 7 on strong inhibitors (e.g. fluoxetine and bupropion). The developed method was used to analyze DBS concentrations of TAM and its metabolites, paired with plasma analyses. Analytes concentrations were highly variable in both matrices, as presented in Table 3 . Median DBS levels in the whole cohort were: TAM 100.0 ng mL [25, 11, 26] . EDF levels were 6.5-fold higher than HTF concentrations, with the 5.7-fold [14] and 6.8-fold [31] previously reported, confirming the predominance of EDF over HTF. Tamoxifen, NDT, EDF and HTF concentrations in DBS were in average 80%, 77%, 59% and 72% of those measured in plasma. EPC were calculated from DBS concentrations after adjustment by patients Hct% and using the correction factors of 0.84; 0.78; 1.12; 0.87 for TAM, NDT, EDF and HTF respectively. After Hct% and factor correction, median estimated plasma levels were: TAM 123.3 ng mL , thus estimated levels represented in average 98 to 104% of the actually measured plasma concentrations. The differences between EPC and Estimated plasma concentrations (EPC) of TAM and metabolites were also compared to measured plasma concentrations (MPC) by Bland-Altman plots (Fig. 2) . The mean difference of the concentrations in plasma and estimated plasma concentrations using individual Hct% were 4.0 ng mL À 1 for TAM, À 0.7 ng mL (Fig. 3) . Using the DBS proposed threshold, as previously observed on estimated plasma results, we were able to identify 23 of 24 samples with measured plasma concentrations o5.9 ng mL À 1 . The high prevalence of patients with low EDF levels could be related to the high frequency of use of inhibitor drugs (20%) and other factors such as genetic polymorphisms of CYP2D6 and/or other enzymes to be further evaluated.
Additionally we compared DBS and estimated plasma EDF concentrations between groups of measured EDF above or below 5.9 ng mL À 1 and found reduced levels at the last group as well: median EDF DBS 2.0 ng mL À 1 vs 7.0 ng mL À 1 and 3.6 ng mL À 1 vs 12.5 ng mL À 1 (Po0.01), for DBS and estimated plasma respectively.
Similarly DBS and estimated plasma [NDT]/[EDF] metabolic ratio were also significantly different between groups of EDF plasma levels ( Table 4 ). In summary, the DBS method was able to identify with high accuracy (96%) patients with plasma EDF levels below the clinical threshold related to better prognosis as well as impaired CYP2D6 metabolism through [NDT]/[EDF] metabolic ratio.
Conclusions
A method for determination of TAM and its major metabolites in DBS using LC-MS/MS was developed and validated. Transport and storage of DBS samples require special attention, since EDF and HTF concentrations in control samples increased after storage at 45 1C. TAM, NDT, EDF, HTF concentrations in DBS and estimated plasma were highly correlated to measured plasma concentrations. We found a high prevalence of patients with EDF level below the clinical threshold of 5.9 ng mL À 1 which were effectively identified through DBS samples. These findings suggest that DBS based therapeutic monitoring of TAM can be an efficient tool to optimize adjuvant breast cancer treatment, allowing patients to collect blood samples at their home within the appropriate time to obtain trough samples, facility transport conditions and handling safety. In addition, our results also offer insight into the effects of CYP2D6 inhibitors on TAM metabolism to EDF.
